Antidepressants in Alzheimer's Disease: A Focus on the Role of Mirtazapine

被引:27
作者
Correia, Ana Salome [1 ,2 ]
Vale, Nuno [1 ,3 ]
机构
[1] Ctr Hlth Technol & Serv Res CINTESIS, OncoPharma Res Grp, Rua Doutor Placido da Costa, P-4200450 Porto, Portugal
[2] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal
[3] Univ Porto, Fac Med, Dept Community Med Hlth Informat & Decis MEDCIDS, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal
关键词
Alzheimer's disease; depression; mirtazapine; MILD COGNITIVE IMPAIRMENT; SEROTONIN REUPTAKE INHIBITORS; OBSESSIVE-COMPULSIVE DISORDER; MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND; AMYLOID-BETA; OPEN-LABEL; SLEEP ARCHITECTURE; MOUSE MODEL; SERTRALINE;
D O I
10.3390/ph14090930
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Mirtazapine belongs to the category of antidepressants clinically used mainly in major depressive disorder but also used in obsessive-compulsive disorders, generalized anxiety, and sleep disturbances. This drug acts mainly by antagonizing the adrenergic alpha 2, and the serotonergic 5-HT2 and 5-HT3 receptors. Neuropsychiatric symptoms, such as depression and agitation, are strongly associated with Alzheimer's disease, reducing the life quality of these patients. Thus, it is crucial to control depression in Alzheimer's patients. For this purpose, drugs such as mirtazapine are important in the control of anxiety, agitation, and other depressive symptoms in these patients. Indeed, despite some contradictory studies, evidence supports the role of mirtazapine in this regard. In this review, we will focus on depression in Alzheimer's disease, highlighting the role of mirtazapine in this context.
引用
收藏
页数:15
相关论文
共 115 条
[1]   Depression in Alzheimer's Disease: A Delphi Consensus on Etiology, Risk Factors, and Clinical Management [J].
Aguera-Ortiz, Luis ;
Garcia-Ramos, Rocio ;
Grandas Perez, Francisco J. ;
Lopez-Alvarez, Jorge ;
Montes Rodriguez, Jose Manuel ;
Olazaran Rodriguez, F. Javier ;
Olivera Pueyo, Javier ;
Pelegrin Valero, Carmelo ;
Porta-Etessam, Jesus .
FRONTIERS IN PSYCHIATRY, 2021, 12
[2]  
Al-Majed A, 2018, PROF DRUG SUB EXCIP, V43, P209, DOI 10.1016/bs.podrm.2018.01.002
[3]  
Alam A., 2013, PRIM CARE COMPANION, V15, DOI [10.4088/PCC.13r01525, DOI 10.4088/PCC.13R01525]
[4]   An Open-Label Study of Mirtazapine as Treatment for Combat-Related PTSD [J].
Alderman, Christopher P. ;
Condon, John T. ;
Gilbert, Andrew L. .
ANNALS OF PHARMACOTHERAPY, 2009, 43 (7-8) :1220-1226
[5]   Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response [J].
Andrews, Paul W. ;
Bharwani, Aadil ;
Lee, Kyuwon R. ;
Fox, Molly ;
Thomson, J. Anderson, Jr. .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2015, 51 :164-188
[6]   Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study [J].
Bahk, WM ;
Pae, CU ;
Tsoh, J ;
Chae, JH ;
Jun, TY ;
Chul-Lee ;
Kim, KS .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2002, 17 (07) :341-344
[7]   Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial [J].
Banerjee, Sube ;
Hellier, Jennifer ;
Dewey, Michael ;
Romeo, Renee ;
Ballard, Clive ;
Baldwin, Robert ;
Bentham, Peter ;
Fox, Chris ;
Holmes, Clive ;
Katona, Cornelius ;
Knapp, Martin ;
Lawton, Claire ;
Lindesay, James ;
Livingston, Gill ;
McCrae, Niall ;
Moniz-Cook, Esme ;
Murray, Joanna ;
Nurock, Shirley ;
Orrell, Martin ;
O'Brien, John ;
Poppe, Michaela ;
Thomas, Alan ;
Walwyn, Rebecca ;
Wilson, Kenneth ;
Burns, Alistair .
LANCET, 2011, 378 (9789) :403-411
[8]  
Barkin R L, 2000, Am J Ther, V7, P205, DOI 10.1097/00045391-200007030-00008
[9]   Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression [J].
Bartels, Claudia ;
Wagner, Michael ;
Wolfsgruber, Steffen ;
Ehrenreich, Hannelore ;
Schneider, Anja .
AMERICAN JOURNAL OF PSYCHIATRY, 2018, 175 (03) :232-241
[10]   Mirtazapine orally disintegrating tablet versus sertraline:: A prospective onset of action study [J].
Behnke, K ;
Sogaard, J ;
Martin, S ;
Bäuml, J ;
Ravindran, AV ;
Ågren, H ;
Vester-Blokland, ED .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) :358-364